143 related articles for article (PubMed ID: 25574959)
1. Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.
Borges ÁH; Lundgren JD; Ridolfo A; Katlama C; Antunes F; Grzeszczuk A; Blaxhult A; Mitsura VM; Doroana M; Battegay M; Gargalianos P; Mocroft A;
AIDS; 2014 Nov; 28(17):2565-71. PubMed ID: 25574959
[TBL] [Abstract][Full Text] [Related]
2. Deteriorating renal function and clinical outcomes in HIV-positive persons.
Mocroft A; Ryom L; Begovac J; Monforte AD; Vassilenko A; Gatell J; Florence E; Ormaasen V; Kirk O; Lundgren JD;
AIDS; 2014 Mar; 28(5):727-37. PubMed ID: 24983543
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort.
Pacheco YM; Jarrin I; Rosado I; Campins AA; Berenguer J; Iribarren JA; Rivero M; Muñoz-Medina L; Bernal-Morell E; Gutiérrez F; Leal M;
Antiviral Res; 2015 May; 117():69-74. PubMed ID: 25766861
[TBL] [Abstract][Full Text] [Related]
4. Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy.
Galli L; Spagnuolo V; Poli A; Salpietro S; Gianotti N; Cossarini F; Carbone A; Nozza S; Bossolasco S; Bigoloni A; Lazzarin A; Castagna A
AIDS; 2014 Oct; 28(16):2407-15. PubMed ID: 25160933
[TBL] [Abstract][Full Text] [Related]
5. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
6. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
[TBL] [Abstract][Full Text] [Related]
7. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy.
Masiá M; Padilla S; Álvarez D; López JC; Santos I; Soriano V; Hernández-Quero J; Santos J; Tural C; del Amo J; Gutiérrez F;
AIDS; 2013 Jan; 27(2):181-9. PubMed ID: 23018442
[TBL] [Abstract][Full Text] [Related]
8. Infection-related and -unrelated malignancies, HIV and the aging population.
Shepherd L; Borges Á; Ledergerber B; Domingo P; Castagna A; Rockstroh J; Knysz B; Tomazic J; Karpov I; Kirk O; Lundgren J; Mocroft A;
HIV Med; 2016 Sep; 17(8):590-600. PubMed ID: 26890156
[TBL] [Abstract][Full Text] [Related]
9. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.
Mocroft A; Furrer HJ; Miro JM; Reiss P; Mussini C; Kirk O; Abgrall S; Ayayi S; Bartmeyer B; Braun D; Castagna A; d'Arminio Monforte A; Gazzard B; Gutierrez F; Hurtado I; Jansen K; Meyer L; Muñoz P; Obel N; Soler-Palacin P; Papadopoulos A; Raffi F; Ramos JT; Rockstroh JK; Salmon D; Torti C; Warszawski J; de Wit S; Zangerle R; Fabre-Colin C; Kjaer J; Chene G; Grarup J; Lundgren JD;
Clin Infect Dis; 2013 Oct; 57(7):1038-47. PubMed ID: 23921881
[TBL] [Abstract][Full Text] [Related]
10. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.
Cozzi-Lepri A; Zangerle R; Machala L; Zilmer K; Ristola M; Pradier C; Kirk O; Sambatakou H; Fätkenheuer G; Yust I; Schmid P; Gottfredsson M; Khromova I; Jilich D; Flisiak R; Smidt J; Rozentale B; Radoi R; Losso MH; Lundgren JD; Mocroft A;
HIV Med; 2018 Feb; 19(2):102-117. PubMed ID: 28984429
[TBL] [Abstract][Full Text] [Related]
11. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009.
Calabresi A; Ferraresi A; Festa A; Scarcella C; Donato F; Vassallo F; Limina R; Castelli F; Quiros-Roldan E;
HIV Med; 2013 Sep; 14(8):481-90. PubMed ID: 23560682
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients.
Lichtner M; Cicconi P; Vita S; Cozzi-Lepri A; Galli M; Lo Caputo S; Saracino A; De Luca A; Moioli M; Maggiolo F; Marchetti G; Vullo V; d'Arminio Monforte A;
J Infect Dis; 2015 Jan; 211(2):178-86. PubMed ID: 25081936
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.
Mendeni M; Focà E; Gotti D; Ladisa N; Angarano G; Albini L; Castelnuovo F; Carosi G; Quiros-Roldan E; Torti C
Clin Infect Dis; 2011 May; 52(9):1164-73. PubMed ID: 21467023
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users.
Harboe ZB; Larsen MV; Ladelund S; Kronborg G; Konradsen HB; Gerstoft J; Larsen CS; Pedersen C; Pedersen G; Obel N; Benfield T
Clin Infect Dis; 2014 Oct; 59(8):1168-76. PubMed ID: 25038114
[TBL] [Abstract][Full Text] [Related]
16. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project.
Sullivan PS; Hanson DL; Chu SY; Jones JL; Ciesielski CA
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Apr; 14(4):374-9. PubMed ID: 9111481
[TBL] [Abstract][Full Text] [Related]
17. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV.
Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
Clin Infect Dis; 2013 Jul; 57(2):314-21. PubMed ID: 23575194
[TBL] [Abstract][Full Text] [Related]
18. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
Monforte Ad; Reiss P; Ryom L; El-Sadr W; Dabis F; De Wit S; Worm SW; Law MG; Weber R; Kirk O; Pradier C; Phillips AN; Lundgren JD; Sabin CA
AIDS; 2013 Jan; 27(3):407-15. PubMed ID: 23291539
[TBL] [Abstract][Full Text] [Related]
20. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
